Trial Profile

Auxora for the Treatment of AKI and Modulation of Injurious "Crosstalk" With the Lung: A Randomized Control Trial (KOURAGE)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jun 2025 According to a CalciMedica media release, the design and rationale of the Company's Phase 2 KOURAGE trial of lead candidate Auxora™ in acute kidney injury (AKI) with respiratory failure has been published in the American Journal of Nephrology. The publication also highlights the rationale for the patient selection and endpoint selection for this study. It was co-authored by Lakhmir Chawla, M.D., Clinical Professor of Medicine at University of California San Diego, along with others.
22 Apr 2025 Planned End Date changed from 1 Aug 2025 to 1 Mar 2026.
22 Apr 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Mar 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com